RDY
Dr. Reddy's Laboratories Limited
Set alert
- YTD
- +0.93%
- 1 year
- +5.35%
- Open
- 14.20
- Prev close
- 14.11
- Mkt cap
- 11.80B
- Vol
- 1.81M
- Avg vol
- 2.93M
- EPS
- 0.36
- P/E
- 39.36
- Div yield
- 0.59%
More statistics
- Low
- 14.15
- High
- 14.29
- Forward P/E
- 21.39
- Beta
- 0.25
- Short ratio
- 8.16
- Inst. own
- 14.93%
- Dividend
- 0.08
- Ex-div date
- Jul 8, 2026
- Earnings
- Jan 22, 2027
- 50-d avg
- 12.50
- 200-d avg
- 13.21
- 1y target
- 14.31
Key statistics
- Market cap
- 11.81B
- Enterprise value
- 69.62B
- Trailing P/E
- 39.38
- Forward P/E
- 21.39
- PEG ratio
- 1.96
- Price / sales
- 0.04
- Price / book
- 17.27
- EPS (TTM)
- 0.36
- Beta
- 0.25
- Dividend yield
- 0.59%
- Payout ratio
- 22.72%
- Profit margin
- 8.48%
- Revenue (TTM)
- 329.84B
- Revenue growth
- -1.50%
- Free cash flow
- -6.59B
- Total cash
- 76.24B
- Total debt
- 72.29B
- Return on equity
- 7.34%
- Shares outstanding
- 833.07M
- Short % of float
- 3.81%
- 50-day average
- 12.50
- 200-day average
- 13.21
Analyst view
Consensus: buy
- Target (low)
- 12.50
- Target (mean)
- 14.31
- Target (high)
- 15.70
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Jan 22, 2027
Expected Jan 22, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 22, 2027 | Dec 30, 2026 | 0.15 | — | — | — |
| Oct 23, 2026 | Sep 30, 2026 | 0.09679 | 0.12 | +0.02 | +23.98% |
| Jul 21, 2026 | Jun 30, 2026 | 0.09182 | 0.06 | -0.03 | -34.65% |
| May 11, 2026 | Mar 31, 2026 | 0.09 | 0.06 | -0.03 | -33.33% |
| Jan 20, 2026 | Dec 31, 2025 | 0.16 | 0.16 | 0.00 | 0.00% |
| Oct 24, 2025 | Sep 30, 2025 | 0.18 | 0.19 | +0.01 | +5.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 2026 | Citigroup | up | Sell | Buy |
| Jun 5, 2025 | HSBC | up | Hold | Buy |
| Nov 6, 2024 | Barclays | main | Overweight | Overweight |
| Jul 30, 2024 | Barclays | main | Overweight | Overweight |
| May 8, 2024 | Barclays | main | Overweight | Overweight |
| Jan 29, 2024 | Barclays | main | Overweight | Overweight |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- India
- Website
- drreddys.com
News
- RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
- Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
- Dr Reddy's Laboratories Q2 2027 Earnings Call Transcript
- Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate
- American Express, Eni On Deck Friday As Spending, Energy Demand Face Test
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450
- Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
- Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
- Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M Estimate
Your note
Sign in to keep a note on RDY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 1.31% | 10,936,320 | 155.02M | Jun 29, 2026 |
| Blackrock Inc. | 1.27% | 10,585,742 | 150.05M | Jun 29, 2026 |
| Royal Bank of Canada | 1.10% | 9,213,269 | 130.60M | Jun 29, 2026 |
| Robeco Institutional Asset Management B.V. | 1.04% | 8,680,810 | 123.05M | Sep 29, 2026 |
| Aikya Investment Management Ltd | 1.02% | 8,493,852 | 120.40M | Jun 29, 2026 |
| Renaissance Technologies, LLC | 0.88% | 7,347,028 | 104.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares, Inc.-iShares Core MSCI Emerging Markets ETF | 0.69% | 5,728,507 | 81.20M | Sep 29, 2026 |
| AB Active ETFs, Inc.-AB Emerging Markets Opportunities ETF | 0.45% | 3,744,214 | 53.07M | Aug 30, 2026 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 0.24% | 2,031,281 | 28.79M | Jun 29, 2026 |
| VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Emerging Markets Stock Index Fd | 0.22% | 1,873,980 | 26.56M | Jul 30, 2026 |
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.22% | 1,811,312 | 25.68M | Sep 29, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF | 0.18% | 1,461,987 | 20.72M | Sep 29, 2026 |